Search

Your search keyword '"Cheng Su-Chun"' showing total 307 results

Search Constraints

Start Over You searched for: Author "Cheng Su-Chun" Remove constraint Author: "Cheng Su-Chun"
307 results on '"Cheng Su-Chun"'

Search Results

1. A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib

2. Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses

3. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours

4. Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer

5. Centralized Interactive Phenomics Resource: an integrated online phenomics knowledgebase for health data users

6. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial

7. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

9. A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

11. The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma

14. Report on the PET/CT Image–Based Radiation Dosimetry of [18F]FDHT in Women, a Validated Imaging Agent with New Applications for Evaluation of Androgen Receptor Status in Women with Metastatic Breast Cancer

18. Data from Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

19. Supplemental Table 1 from Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

20. Supplemental Table 2 from Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

21. Supplementary Data from FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma

24. A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor–Positive Recurrent Endometrial Cancer

25. Killer immunoglobulin-like receptor (KIR) and KIR–ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2

26. Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer

31. Phase 2, two-stage study of letrozole and abemaciclib in estrogen receptor (ER) positive recurrent or persistent endometrial cancer (072)

32. Activity of combination trametinib/navitoclax in patients with RAS-mutated gynecologic (GYN) cancers in a Phase 1/2 study (LBA 12)

36. Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer

38. Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers

39. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours

47. Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer

49. Effects of Kinesio taping and exercise on forward head posture

Catalog

Books, media, physical & digital resources